Skip to main content
RheumNow’s expanded coverage of the #ACR25 meeting is sponsored by Bristol Myers Squibb, Novartis, and UCB. All covera

Dr. John Cush RheumNow

9 months ago
RheumNow’s expanded coverage of the #ACR25 meeting is sponsored by Bristol Myers Squibb, Novartis, and UCB. All coverage content is selected by RheumNow and its faculty.
Day 1 Recap: #ACR25 Highlights

Join RheumNow Faculty Drs. Aurelie Najm, Yuz Yusof, Janet Pope, and Jack Cush for Day 1

Dr. John Cush RheumNow

9 months ago
Day 1 Recap: #ACR25 Highlights Join RheumNow Faculty Drs. Aurelie Najm, Yuz Yusof, Janet Pope, and Jack Cush for Day 1 highlights from the 2025 ACR Convergence in Chicago, focusing on abstracts/sessions: 0775, SLE guidelines, 0163, 0832, 0776, 0792, and 0164. https://t.co/ODte4XY82a
Ankylosing spondylitis (AS) is a burden on the bones—both literally and diagnostically. The disease’s dual nature, marked by chronic inflammation and abnormal new bone formation, complicates the assessment of bone health. While inflammation erodes trabecular bone, syndesmophytes and ligamentous calcifications can falsely elevate spine bone mineral density (BMD) readings on standard dual-energy X-ray absorptiometry (DXA).
GLP-1 Receptor Agonists in PsA: Mortality and MACE https://t.co/GtTGHY7j5g

@synovialjoints discussed TriNetX data bas

Nouf Al hemmadi NoufAhmedAlham2

9 months ago
GLP-1 Receptor Agonists in PsA: Mortality and MACE https://t.co/GtTGHY7j5g @synovialjoints discussed TriNetX data base looking at GLP-1 medications effect on MACE in PsA patients. @RheumNow #ACR25
NEPTUNUS: Ianalumab in Sjogren's https://t.co/K9Xm51Kb5X

Finally good news in Sjogrens disease.

@RheumNow
#ACR25

Nouf Al hemmadi NoufAhmedAlham2

9 months ago
NEPTUNUS: Ianalumab in Sjogren's https://t.co/K9Xm51Kb5X Finally good news in Sjogrens disease. @RheumNow #ACR25
Why are vaccine Abs maintained after CAR-T
-depletion of pathogenic #Abs are dampened/eliminated
Clonal repetoire expan

Janet Pope Janetbirdope

9 months ago
Why are vaccine Abs maintained after CAR-T -depletion of pathogenic #Abs are dampened/eliminated Clonal repetoire expansion Remission=naive B cell pop'n Reset immune system sparing memory cells vs ?not all pathogenic cells eliminated in tissue #ACR25 @RheumNow @ACRheum #26S21 https://t.co/jb3dD5Ssip
Day 4 Recap: ACR Convergence 2025 Highlights https://t.co/CMpbzc4O5x

Great discussion by @EBRheum @AkhilSoodMD @Dr_B

Nouf Al hemmadi NoufAhmedAlham2

9 months ago
Day 4 Recap: ACR Convergence 2025 Highlights https://t.co/CMpbzc4O5x Great discussion by @EBRheum @AkhilSoodMD @Dr_Brian_MD . I have always been a FK fan in lupus nephritis as an add on therapy , the only inconvenience is regular monitoring. @RheumNow #ACR25
From Fitbit to first diagnosis: AI is rewriting the RA playbook

Two studies presented at this year’s #ACR25 meeting h

Dr. John Cush RheumNow

9 months ago
From Fitbit to first diagnosis: AI is rewriting the RA playbook Two studies presented at this year’s #ACR25 meeting highlight just how close we may be to a future where algorithms flag disease before we can and monitor activity with minimal patient burden. https://t.co/8AwBZkyZIW
New Insights into Pregnancy Outcomes and Maternal-Fetal Health in Rheumatic Diseases

At #ACR25, the ACR presented new

Dr. John Cush RheumNow

9 months ago
New Insights into Pregnancy Outcomes and Maternal-Fetal Health in Rheumatic Diseases At #ACR25, the ACR presented new research illuminating critical challenges and advances in pregnancy outcomes for women living with rheumatic diseases, including axial spondyloarthritis, https://t.co/nJjtTMHnD3
Day 1 Recap: #ACR25 Highlights

Join RheumNow Faculty Drs. Aurelie Najm, Yuz Yusof, Janet Pope and Jack Cush as they di

Dr. John Cush RheumNow

9 months ago
Day 1 Recap: #ACR25 Highlights Join RheumNow Faculty Drs. Aurelie Najm, Yuz Yusof, Janet Pope and Jack Cush as they discuss highlights and key takeaways from the Day 1 Recap on Sunday, October 26th. https://t.co/Kq8TDBLUYZ https://t.co/TNM8ZAji9w
CAR T
Which cells to target
What patients & what disease
When is right time
In vivo (new) ex vivo
Premeds immune sup

Janet Pope Janetbirdope

9 months ago
CAR T Which cells to target What patients & what disease When is right time In vivo (new) ex vivo Premeds immune suppression What to use, ?if anything Cons Is it safe ?long term effectiveness What is failure rate ICANs and other side effects #ACRBest #ACR25 @RheumNow #26S21 https://t.co/TUSJh1hrPr https://t.co/JiqYzgBmYP
×